BioDelivery Sciences (BDS) Announces $1.3M U.S. Army Grant
Up)
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) received a $1.3 million grant from the Walter Reed Army Institute of Research for Bioral Amphotericin B, an oral formulation of the fungicidal treatment amphotericin B in BDSI’s patented Bioral drug delivery technology, to further study the formulation in the treatment of Cutaneous Leishmaniasis.
You May Also Be Interested In
- DISH Network (DISH) Sued by Networks for 'Commercial Skipping' Feature
- PDI, Inc. (PDII) Enters New $57M PCP Targeting Contract
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
